Nearly half of PBC patients in US haven’t seen a specialist recently
About 40 in every 100,000 U.S. adults have primary biliary cholangitis (PBC), with its frequency, when adjusted to population size, being highest in some…
Cholangitis
EMA to review linerixibat for itch in primary biliary cholangitis
The European Medicines Agency (EMA) will review an application for linerixibat, an experimental oral therapy for intense itching associated with primary biliary cholangitis (PBC).
Mononucleosis linked to higher risk of developing PSC: Study
Note: This story was updated Aug. 8, 2025, to correct that infectious mononucleosis was linked to a 4.6 times higher risk of future PSC, not  a…
Trial of golexanolone for PBC cognitive symptoms to resume
A Phase 1b/2a clinical trial of golexanolone, Umecrine Cognition’s candidate therapy for cognitive symptoms and fatigue related to primary biliary cholangitis (PBC), will resume…
FDA to review linerixibat for PBC-related itching
The U.S. Food and Drug Administration (FDA) has accepted for review GSK’s application seeking the approval of its oral treatment linerixibat for intense itching, or…
30% rise due in primary sclerosing cholangitis prevalence by 2040
The global prevalence of primary sclerosing cholangitis (PSC), or the total number of existing cases, is expected to increase substantially over the next several…
Linerixibat reduces itch, improves sleep in PBC Phase 3 trial
Nearly six months of treatment with the experimental oral candidate linerixibat significantly reduced itch and itch-related sleep problems for adults with primary biliary cholangitis…
Even with past treatment, Livdelzi works on primary biliary cholangitis
The efficacy of Livdelzi (seladelpar) at treating primary biliary cholangitis (PBC) is similar irrespective of whether patients previously received other medications, according to…
RTY-694 shows promise in models of liver, bile duct diseases PFIC, PSC
An experimental oral therapy by Rectify Pharmaceuticals called RTY-694 reduced markers of slowed bile flow and inflammation in a mouse model of progressive…
New primary sclerosing cholangitis treatment to target ACLY enzyme
With ESP-1336 as their lead candidate, Esperion Therapeutics is developing new treatments for primary sclerosing cholangitis (PSC) by targeting an enzyme called ACLY.
Recent Posts
- Virtual 5K expands annual run into national biliary atresia fundraiser
- Phase 3 Trial of brelovitug for hepatitis D enrolls 1st patient
- Groups unite to fight liver disease during PBC Awareness Month
- Taking care of our teeth is crucial with liver disease
- LSR gene mutations may cause new type of rare liver disease PFIC